Fludarabine Phosphate
NDC Package 52152-609-55

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Fludarabine Phosphate is a medication used to treat leukemia and other cancers. Marketed by Actavis Totowa Llc, this product is identified by NDC 52152-609 and is authorized under FDA application ANDA078610.

Identification & Billing

NDC Package Code
52152-609-55
Package Description
1 VIAL, GLASS in 1 CARTON / 2 mL in 1 VIAL, GLASS
Product Code
52152-609
11-Digit Billing Format
52152060955

Clinical Specifications

Proprietary Name
Fludarabine Phosphate
Dosage Form
-
Usage Information
This medication is used to treat leukemia and other cancers. It works by slowing or stopping the growth of cancer cells.

Regulatory & Marketing

Labeler Name
Actavis Totowa Llc
FDA Application #
ANDA078610
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-20-2009
End Marketing Date
03-20-2009
Listing Expiration
03-20-2009
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 52152-609-55 identifies a specific commercial package of 1 vial, glass in 1 carton / 2 ml in 1 vial, glass of Fludarabine Phosphate, labeled by Actavis Totowa Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Actavis Totowa Llc on March 20, 2009. The current certification is valid through March 20, 2009.

What are the primary indications for this medication?

This medication is used to treat leukemia and other cancers. It works by slowing or stopping the growth of cancer cells.

How is this Actavis Totowa Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 52152060955. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
52152-609-55
11-Digit CMS (5-4-2)
52152-0609-55

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.